Videos

Remote therapeutic monitoring significantly lowers infection-related hospitalizations in hematological cancer patients, enhancing outpatient care and reducing emergency visits.

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.

Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient outcomes.

Long-term follow-up of the TRANSFORM study reveals liso-cel's impressive efficacy and safety in treating relapsed large B-cell lymphoma.

Comprehensive biomarker testing at the time of early NSCLC diagnosis is critical because it ensures that clinicians identify actionable molecular alterations before definitive treatment plans are set.

Panelists discuss how trial data and practical considerations inform the nuanced choice between amivantamab–lazertinib and osimertinib in managing EGFR-mutant non–small-cell lung cancer (NSCLC) with CNS disease.

Panelists discuss how personalized molecular insights drive first-line therapy choices in EGFR-mutant NSCLC with complex metastatic profiles.

Comprehensive biomarker testing in early-stage NSCLC requires coordination across multiple specialties, including thoracic surgery, medical oncology, pathology, pulmonology, and radiology.

The ACCESS study reveals that posttransplant cyclophosphamide improves survival rates for patients with mismatched unrelated donor transplants, expanding donor options.

Heather Stefanski, MD, PhD, discusses the unmet needs for patients undergoing bone marrow and stem cell transplants.

Peter Voorhees, MD, discusses the evolving treatment landscape for smoldering multiple myeloma, highlighting new therapies and clinical trial opportunities.

Dr. Peter Voorhees discusses risk stratification in smoldering multiple myeloma, highlighting the IMWG criteria and the benefits of daratumumab treatment.

Peter Voorhees, MD, discusses groundbreaking AQUILA study results, highlighting daratumumab's significant impact on high-risk smoldering multiple myeloma treatment.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

Che-Kai Tsao, MD, MS, discusses new approaches that could change the standard of care for metastatic hormone-sensitive prostate cancer.

Peter Voorhees, MD, discusses the AQUILA study's impact on treating patients with high-risk smoldering multiple myeloma, paving the way for new therapies.

This discussion looks ahead at how the role of PD-1 inhibitors may continue to evolve in the treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (GEJ) cancers.

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the management of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (GEJ) cancers.

This discussion highlights several emerging therapeutic approaches that are shaping future directions in advanced gastric and gastroesophageal junction (GEJ) cancers.

This discussion outlines several emerging therapeutic approaches currently under investigation for advanced gastric and gastroesophageal junction (GEJ) cancers.

This discussion reviews the dosing flexibility available for PD-1 inhibitors used in advanced gastric and gastroesophageal junction (GEJ) cancers.

This discussion reviews the dosing flexibility available for PD-1 inhibitors used in advanced gastric and gastroesophageal junction (GEJ) cancers.

This discussion reviews the key safety considerations for checkpoint inhibitors used in advanced esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (GEJ) cancers.

This discussion reviews key safety considerations for immune checkpoint inhibitors used in advanced esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (GEJ) cancers.

This discussion reviews the ongoing HERIZON-GEA-01 trial, a global, randomized Phase 3 study evaluating zanidatamab as a potential first-line treatment for HER2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma.

This discussion reviews the ongoing HERIZON-GEA-01 trial, a global Phase 3 study evaluating zanidatamab as part of first-line therapy for HER2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma.

This discussion summarizes the KEYNOTE-811 trial, which evaluated the addition of pembrolizumab to trastuzumab and platinum-based chemotherapy for patients with previously untreated, HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

This discussion reviews the KEYNOTE-811 trial, which evaluates the addition of pembrolizumab to trastuzumab and chemotherapy in the first-line treatment of HER2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma.

This discussion provides a focused overview of the RATIONALE-305 trial, which evaluated tislelizumab in combination with platinum-based chemotherapy as first-line treatment for patients with previously untreated, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Emerging MRD tests show promise in enhancing breast cancer treatment by improving risk stratification and clinical outcomes for patients.